Innate Pharma Results and Business Update

 

• Phase 1/2 dose escalation safety and preliminary efficacy of ANKET^® NK cell engager, SAR'579/IPH6101, developed by Sanofi, showed it was well tolerated with observed clinical benefit in patients with R/R AML (ASCO 2023 annual meeting), FDA Fast Track Designation awarded
• Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; $5m upfront payment to Innate and up to $410m in future milestones plus royalties
• Proprietary ANKET^® IPH65 IND approved, progressing to Phase 1
• Proprietary IPH45 ADC target, nectin-4 disclosed
• Innate announces new Chief Medical Officer, Sonia Quaratino
• Cash position of €124.7 million¹ as of June 30, 2023, anticipated cash runway into H2 2025
• Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. EDT

Webcast and conference call will be held today at 2:00 p.m. CEST (8:00 a.m. ET)

Access to live webcast:

https://events.q4inc.com/attendee/859850812

Participants may also join via telephone by registering in advance of the event at

https://registrations.events/direct/Q4E60903

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.

https://www.biospace.com/article/releases/innate-pharma-reports-first-half-2023-financial-results-and-business-update/